Enfusion Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Enfusion
ENFN Stock  USD 11.09  0.02  0.18%   
Enfusion financial statements provide useful quarterly and yearly information to potential Enfusion investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Enfusion financial statements helps investors assess Enfusion's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Enfusion's valuation are summarized below:
Gross Profit
136.7 M
Profit Margin
0.014
Market Capitalization
1 B
Enterprise Value Revenue
5.0453
Revenue
201.6 M
We have found one hundred twenty available fundamental signals for Enfusion, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Enfusion's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to grow to about 1.7 B. Also, Enterprise Value is likely to grow to about 1.7 B

Enfusion Total Revenue

142.41 Million

Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion's main balance sheet or income statement drivers, such as Tax Provision of 3.6 M, Net Interest Income of 1.8 M or Depreciation And Amortization of 12.1 M, as well as many indicators such as Price To Sales Ratio of 4.47, Dividend Yield of 0.0034 or PTB Ratio of 13.6. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
  
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Enfusion Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets99.8 M143.3 M53.3 M
Slightly volatile
Short and Long Term Debt Total27 M20.3 M28.2 M
Very volatile
Other Current Liabilities19.9 M19 M4.3 M
Slightly volatile
Total Current Liabilities16.8 M27.3 M11.3 M
Slightly volatile
Other Liabilities411.7 K484.2 K543.7 K
Slightly volatile
Property Plant And Equipment Net22.4 M39 M12.4 M
Slightly volatile
Current Deferred Revenue2.1 M2.2 M5.6 M
Slightly volatile
Accounts Payable1.5 M867 K857.1 K
Slightly volatile
Cash43.4 M54.5 M20.8 M
Slightly volatile
Non Current Assets Total27.4 M49.7 M15 M
Slightly volatile
Non Currrent Assets Other11.3 M10.7 M3 M
Slightly volatile
Other Assets1.091.151.2 M
Very volatile
Long Term Debt67.9 M110.5 M52.3 M
Slightly volatile
Cash And Short Term Investments43.4 M54.5 M20.8 M
Slightly volatile
Net Receivables23 M32 M14.3 M
Slightly volatile
Common Stock Shares Outstanding116.6 M129.6 M110.6 M
Very volatile
Liabilities And Stockholders Equity99.8 M143.3 M53.3 M
Slightly volatile
Non Current Liabilities Total15.6 M16.4 M102.4 M
Slightly volatile
Inventory7.4 M7 M1.7 M
Slightly volatile
Other Current Assets7.1 M7.1 M3.6 M
Slightly volatile
Total Liabilities69.1 M43.7 M116 M
Slightly volatile
Property Plant And Equipment Gross67.9 M64.7 M19.9 M
Slightly volatile
Short and Long Term Debt1.5 M2.9 M1.1 M
Slightly volatile
Total Current Assets72.4 M93.5 M38.3 M
Slightly volatile
Non Current Liabilities Other2.6 M2.5 M1 M
Slightly volatile
Net Working Capital55.6 M66.2 M27 M
Slightly volatile
Short Term Debt5 M6.1 M2.4 M
Slightly volatile
Property Plant Equipment12 M18.1 M9 M
Slightly volatile
Deferred Long Term Liabilities1.3 M1.5 M1.6 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity30.7 M34.6 M37.7 M
Slightly volatile
Common Stock Total Equity91.2 K102.6 K111.9 K
Slightly volatile
Capital Surpluse195.4 M219.8 M239.7 M
Slightly volatile

Enfusion Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision3.6 M3.5 M964.8 K
Slightly volatile
Depreciation And Amortization12.1 M11.5 M3.6 M
Slightly volatile
Interest Expense2 M1.9 M1.2 M
Slightly volatile
Selling General Administrative76.1 M78.8 M40.1 M
Slightly volatile
Selling And Marketing Expenses26.4 M25 M14.8 M
Slightly volatile
Total Revenue142.4 M201.6 M90.7 M
Slightly volatile
Gross Profit98.5 M136.7 M63.4 M
Slightly volatile
Other Operating Expenses188.2 M195.5 M101.3 M
Slightly volatile
Research Development41.7 M26.7 M19.2 M
Slightly volatile
Cost Of Revenue44 M64.9 M27.3 M
Slightly volatile
Total Operating Expenses144.2 M130.6 M74.1 M
Slightly volatile
Reconciled Depreciation6.2 M11.8 M3.1 M
Slightly volatile
Income Tax Expense4.8 M4.6 M1.2 M
Slightly volatile
Interest Income1.4 M1.5 M1.7 M
Slightly volatile

Enfusion Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow34.5 M35.6 M17.1 M
Slightly volatile
Depreciation6.5 M11.8 M3.3 M
Slightly volatile
Capital Expenditures7.1 M3.6 M5.4 M
Slightly volatile
End Period Cash Flow43.4 M54.5 M20.8 M
Slightly volatile
Change To Netincome28.8 M30.4 M25.5 M
Slightly volatile
Change To Liabilities6.3 M6 M1.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.474.702427.4644
Slightly volatile
Dividend Yield0.00340.00270.004
Slightly volatile
Days Sales Outstanding46.757.911656.03
Very volatile
Stock Based Compensation To Revenue0.08970.09441.9704
Slightly volatile
Capex To Depreciation0.290.30932.8329
Slightly volatile
EV To Sales4.314.53327.6743
Slightly volatile
Inventory Turnover6.176.947.57
Slightly volatile
Days Of Inventory On Hand44.7142.5811.3695
Slightly volatile
Payables Turnover78.5774.825840.4374
Slightly volatile
Sales General And Administrative To Revenue0.610.3910.4028
Slightly volatile
Average Inventory2.9 M2.7 M733.6 K
Slightly volatile
Research And Ddevelopement To Revenue0.130.13260.1654
Pretty Stable
Capex To Revenue0.01710.0180.0643
Slightly volatile
Cash Per Share0.380.59190.2334
Slightly volatile
Days Payables Outstanding4.634.87810.5721
Very volatile
Current Ratio3.763.42123.125
Slightly volatile
Receivables Turnover6.896.30276.4785
Slightly volatile
Graham Number0.940.74090.9512
Slightly volatile
Capex Per Share0.05980.03950.0538
Slightly volatile
Revenue Per Share1.182.19040.9211
Slightly volatile
Interest Debt Per Share0.310.22070.2662
Very volatile
Debt To Assets0.130.14180.9356
Slightly volatile
Short Term Coverage Ratios6.246.5627.275
Slightly volatile
Operating Cycle53.0257.911659.3819
Slightly volatile
Days Of Payables Outstanding4.634.87810.5721
Very volatile
Ebt Per Ebit0.781.20050.9498
Very volatile
Quick Ratio3.713.42123.0999
Slightly volatile
Net Income Per E B T0.360.38210.8682
Slightly volatile
Cash Ratio2.311.9931.6383
Slightly volatile
Cash Conversion Cycle42.5253.033648.443
Pretty Stable
Days Of Inventory Outstanding44.7142.5811.3695
Slightly volatile
Days Of Sales Outstanding46.757.911656.03
Very volatile
Cash Flow Coverage Ratios0.941.70750.8016
Slightly volatile
Fixed Asset Turnover8.185.16628.8279
Slightly volatile
Debt Ratio0.130.14180.9356
Slightly volatile
Cash Flow To Debt Ratio0.941.70750.8016
Slightly volatile
Price Sales Ratio4.474.702427.4644
Slightly volatile
Asset Turnover1.81.40732.1598
Slightly volatile
Gross Profit Margin0.770.67820.7111
Very volatile

Enfusion Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B948.1 M1.9 B
Slightly volatile
Enterprise Value1.7 B913.9 M1.9 B
Slightly volatile

Enfusion Fundamental Market Drivers

Forward Price Earnings49.0196
Cash And Short Term Investments54.5 M

Enfusion Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Enfusion Financial Statements

Enfusion investors utilize fundamental indicators, such as revenue or net income, to predict how Enfusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.2 M2.1 M
Total Revenue201.6 M142.4 M
Cost Of Revenue64.9 M44 M
Stock Based Compensation To Revenue 0.09  0.09 
Sales General And Administrative To Revenue 0.39  0.61 
Research And Ddevelopement To Revenue 0.13  0.13 
Capex To Revenue 0.02  0.02 
Revenue Per Share 2.19  1.18 
Ebit Per Revenue 0.03  0.03 
When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
How To Invest In Enfusion
Details
Is Enfusion Stock a good investment?
Details
What is Enfusion's Net Worth?
Details
Largest Application Software Companies
View
Largest Software - Application Companies
View
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.82)
Earnings Share
0.03
Revenue Per Share
2.19
Quarterly Revenue Growth
0.139
Return On Assets
0.0305
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY